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One Sentence Summary: The neurokinin 1 receptor signals from endosomes to induce 
sustained nociception, and antagonists that selectively target the receptor in endosomes provide 





G protein-coupled receptors (GPCRs) are conventionally considered cell-surface sensors 
of extracellular signals. They control most pathophysiological processes and are the target of 
thirty percent of therapeutic drugs. Activated receptors redistribute to endosomes, but whether 
endosomal receptors generate signals that control complex processes in vivo and are viable 
therapeutic targets is unexplored. We report that the substance P (SP) neurokinin 1 receptor 
(NK1R) signals from endosomes to induce sustained excitation of spinal neurons and pain 
transmission, and that specific antagonism of the NK1R in endosomes with membrane-anchored 
drug conjugates provides more effective and sustained pain relief. Pharmacological and genetic 
disruption of clathrin, dynamin and βarr blocked SP-induced NK1R endocytosis, and prevented 
SP-stimulated activation of cytosolic protein kinase C, nuclear extracellular signal regulated, and 
transcription.  Endocytic inhibitors prevented sustained SP-induced excitation of neurons in 
spinal cord slices in vitro, and attenuated nociception in vivo. NK1R antagonists, when 
conjugated to cholestanol to promote endosomal targeting and retention, selectively inhibited 
endosomal signaling and sustained neuronal excitation. Cholestanol conjugation amplified and 
prolonged the anti-nociceptive actions of NK1R antagonists. These results reveal a critical role 
for endosomal signaling of the NK1R in the complex pathophysiology of pain, and demonstrate 





Whereas acute pain allows avoidance of injury and is essential for survival, chronic pain 
accompanies disease (e.g., inflammatory diseases, neuropathies) and therapy (e.g., 
chemotherapy), afflicts twenty percent of individuals at some point of their lives, and is a major 
cause of suffering  (1). The mechanisms that underlie the transition between acute 
(physiological) and chronic (pathological) pain and that sustain chronic pain are unknown. 
Current therapies for chronic pain are often ineffective or produce unacceptable side effects. The 
opioid epidemic, a leading cause of medication-induced death, highlights the need for improved 
pain therapy  (2). 
With almost 1,000 members in humans, G protein-coupled receptors (GPCRs) are the 
largest family of receptors, participate in most physiological and pathophysiological processes, 
and are the target of approximately thirty percent of therapeutic drugs  (3). GPCRs control all 
steps of pain transmission (1, 4). GPCRs at the peripheral terminals of primary sensory neurons 
detect ligands from inflamed and injured tissues, and GPCRs control the activity of second order 
spinal neurons that transmit pain signals centrally. Although GPCRs are a major therapeutic 
target for chronic pain, most GPCR-targeted drugs fail in clinical trials, often for unknown 
reasons (4, 5). 
 GPCRs are conventionally viewed as cell-surface receptors that detect extracellular 
ligands and couple to heterotrimeric G proteins, which trigger plasma membrane-delimited 
signaling events (e.g., second messenger formation, growth factor receptor transactivation, ion 
channel regulation). Activated GPCRs associate with β-arrestins (βarrs), which uncouple 
receptors from G proteins and terminate plasma membrane signaling. βarrs also couple receptors 
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to clathrin and adaptor protein-2 and convey receptors and ligands to endosomes (6). Once 
considered merely a conduit for GPCR trafficking, endosomes are a vital site of signaling (4, 7, 
8). βarrs recruit GPCRs and mitogen-activated protein kinases to endosomes and thereby mediate 
endosomal GPCR signaling (9, 10). Some GPCRs elicit Gαs-dependent signals from endosomes 
(11, 12). GPCR/G protein/βarr complexes also contribute to sustained signaling by internalized 
receptors (13). Although a growing number of GPCRs can signal from endosomes, the 
mechanisms and outcomes of endosomal signaling are incompletely understood, and its 
relevance to complex pathophysiological processes in vivo is unexplored. Drug discovery 
programs aim to identify ligands for cell-surface GPCRs, and whether endosomal GPCRs are a 
therapeutic target remains to be determined. 
We examined the contribution of endocytosis of the neurokinin 1 receptor (NK1R) to 
substance P (SP) -mediated nociception. Painful stimuli release SP from the central projections 
of primary sensory neurons in the dorsal horn of the spinal cord, where SP induces endocytosis 
of the NK1R in second order neurons (5, 14). The NK1R may also be internalized in pain sensing 
regions of the brain of patients with chronic pain (5, 15). We hypothesized that endosomal 
signaling is a critical but unappreciated contributor to pain transmission, and that targeting NK1R 
antagonists to sites of endosomal signaling may provide a novel and effective route to pain relief. 
Thus, the clinical failure of conventional antagonists (5) may relate to their inability to target and 
antagonize the NK1R within multi-protein signalosomes of acidified endosomes. 
 
Results  
Clathrin, Dynamin and βarrs Mediate NK1R Endocytosis 
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To quantify NK1R endocytosis, we used Bioluminescence Resonance Energy Transfer 
(BRET) to assess NK1R proximity to βarrs and resident proteins of plasma (KRas) and early 
endosomal (Rab5a) membranes in HEK293 cells (fig. S1A). SP (1, 10 nM) increased NK1R-
RLuc8/βarr1/2-YFP BRET (fig. S1B,C), which is consistent with βarr-mediated NK1R 
endocytosis (16). SP decreased NK1R-RLuc8/KRas-Venus BRET and concomitantly increased 
NK1R-RLuc8/Rab5a-Venus BRET (fig. S1D-G), indicating NK1R endocytosis. The dynamin 
inhibitor DyngoTM-4a (Dy4) (17), the clathrin inhibitor Pitstop®-2 (PS2) (18), and dominant-
negative dynamin K44E (19) inhibited NK1R endocytosis, whereas inactive analogues (Dy4 
inact, PS2 inact), and wild-type (WT) dynamin had no effect. Dynamin K44E increased the 
NK1R-RLuc8/βarr1/2-YFP BRET, suggesting that endocytosis initiates NK1R/βarr dissociation 
(fig. S1H). Dy4 and PS2 also inhibited endocytosis of fluorescent Alexa568-SP in HEK-NK1R 
cells, causing retention in punctate structures (fig. S1I). These structures may represent 
ligand/receptor clusters in invaginated pits in cells treated with Dy4, or at the plasma membrane 
in cells treated with PS2. Thus, βarrs, clathrin and dynamin mediate SP-induced NK1R 
endocytosis. 
 
NK1R Endocytosis Mediates SP Signaling in Subcellular Compartments 
 To study the link between GPCR endocytosis and signaling in subcellular compartments 
with high spatiotemporal fidelity, we expressed in HEK293 cells the NK1R and Förster 
Resonance Energy Transfer (FRET) biosensors for cytosolic (CytoEKAR) or nuclear 
(NucEKAR) extracellular signal-regulated kinase (ERK) activity, plasma membrane (pmCKAR) 
or cytosolic (CytoCKAR) protein kinase C (PKC) activity, and plasma membrane (pmEpac2) or 
cytosolic (CytoEpac2) cAMP (fig. S2A) (20). SP (1 nM) induced a gradual and sustained 
 6 
activation of nuclear ERK (Fig. 1A-C), and a rapid and sustained activation of cytosolic PKC 
(Fig. 1D-F) and cAMP (Fig. 1G-I). SP rapidly and transiently activated cytosolic ERK (fig. S2B, 
C), did not affect plasma membrane PKC (fig. S2D, E), and increased plasma membrane cAMP 
(fig. S2F, G). Inhibitors of clathrin (PS2) and dynamin (Dy4) abolished SP stimulation of nuclear 
ERK, cytosolic PKC and cytosolic cAMP, indicating a requirement for endocytosis. In contrast, 
PS2 and Dy4 did not affect SP activation of cytosolic ERK or plasma membrane cAMP, which 
do not require endocytosis, but amplified plasma membrane PKC activity. Expression of 
dynamin K44E, but not dynamin WT, prevented SP stimulation of nuclear ERK (Fig. 1J-L). 
Dynamin K44E did not prevent SP stimulation of cytosolic ERK, but caused the response to 
become sustained when compared to dynamin WT (fig. S2H-J). Knockdown of dynamin-1 and 
clathrin heavy chain with siRNA (fig. S2K, L) prevented SP activation of nuclear ERK (Fig. 1M, 
N). 
 Transcription is a major endpoint of GPCR signaling, including activation of nuclear 
ERK, and the β2-adrenergic receptor signals from endosomes to regulate transcription (21). To 
investigate the contribution of NK1R endocytosis to SP-stimulated transcription, we expressed in 
HEK-NK1R cells a reporter encoding secreted alkaline phosphatase (SEAP) under control of the 
serum response element (SRE) transcription factor. SP (10 nM) stimulated SRE-SEAP secretion 
after 4 and 24 h, indicating stimulated transcription (Fig. 1O). Dynamin K44E abolished SP-
stimulated transcription at both times. Dynamin K44E reduced the efficacy but not the potency 
of SP-induced transcription, measured after 24 h (fig. S2M). Thus, NK1R endocytosis is required 
for SP stimulation of transcription. 
 We have previously shown that βarrs mediate NK1R endosomal signaling and nuclear 
ERK activation (9, 22, 23). To examine the contribution of G proteins to endosomal NK1R 
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signaling, we used BRET to study SP-induced trafficking of Gαq to Rab5a-positive early 
endosomes. SP (0.1-10 nM) decreased NK1R-RLuc8/KRas-Venus and increased NK1R-
RLuc8/Rab5a-Venus BRET, demonstrating endocytosis, and decreased Gαq-RLuc8/Gγ2-Venus 
BRET, consistent with G protein activation (Fig. 2A-C; fig. S3A-C). SP increased Gαq-
RLuc8/Rab5a-Venus BRET, which indicates Gαq translocation to early endosomes containing 
NK1R (Fig. 2D; fig. S3D). We used immunofluorescence and super-resolution microscopy to 
localize NK1R-immunoreactivity (IR), Gαq-IR and early endosomal antigen 1 (EEA1)-IR. When 
cells were treated with SP at 4°C, NK1R-IR and Gαq-IR colocalized at the plasma membrane but 
were not detected in endosomes (Fig. 2E). After incubation with SP at 37°C, NK1R-IR and Gαq-
IR colocalized with EEA1-IR in endosomes (Fig. 2E,F). 
 The Gαq inhibitor UBO-QIC prevented SP activation of nuclear ERK (Fig. 2G; fig. S3E), 
which also depends on βarrs and PKC but not epidermal growth factor receptor transactivation 
(9, 22, 23). UBO-QIC, the phospholipase C (PLC) inhibitor U73122 and the Ca2+ chelator EGTA 
prevented activation of cytosolic PKC (Fig. 2H; fig. S3F), consistent with a Gαq, PLC and Ca2+-
dependent PKC pathway. UBO-QIC, the PKC inhibitor GF109203X and EGTA, but not the Gαs 
inhibitor NF449, prevented SP generation of cytosolic cAMP (Fig. 2I; fig. S3G), supporting a 
role for Gαq-mediated activation of Ca2+-dependent PKC in the generation of cAMP. UBO-QIC 
did not affect NK1R endocytosis (fig. S3H). In addition to inhibiting PKCa (4% control), 
GF109203X (Bis-1) also inhibits other kinases (24), which may also contribute to SP signaling. 
 These results support the hypothesis that SP and the NK1R signal from endosomes by 
Gαq-mediated mechanisms to activate nuclear ERK and cytosolic PKC and cAMP. 
 
Endocytosis Mediates Sustained SP-evoked Excitation of Spinal Neurons 
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The NK1R mediates nociceptive transmission in second order spinal neurons, where 
painful stimuli induce SP release, NK1R endocytosis and ERK activation (5, 14, 25). SP causes 
persistent NK1R-dependent excitation of spinal neurons by unknown mechanisms (26). To 
evaluate whether NK1R endosomal signaling mediates this sustained excitation, we made cell-
attached patch clamp recordings from NK1R-positive neurons in lamina I of the dorsal horn in 
slices of rat spinal cord. SP (1 µM, 5 min) stimulated NK1R-IR endocytosis in spinal neurons 
(Fig. 3A,B). Brief exposure to SP (1 µM, 2 min) triggered rapid onset action potential firing that 
was sustained after washout (Fig. 3C-E). Dy4 but not Dy4 inact inhibited NK1R endocytosis. 
Dy4 did not affect the initial onset of SP-induced firing, but prevented the sustained response, 
reducing both the firing rate and firing time, whereas Dy4 inact had no effect. The SP-induced 
firing rate (2 min normalized) was (events.2 min-1) Dy4, 342.1±120.7 and Dy4 inact, 
569.0±187.6 (P<0.05). 
To define the signaling pathway that mediates SP-evoked excitation of spinal neurons, 
slices were preincubated with inhibitors of MEK (U0126) or PKC (GF109203X) or vehicle 
(control). U0126 inhibited SP-induced firing time of lamina I neurons by 67.5±8.3% (control, 
10.01±1.8 min, n=10 cells, 8 rats; U0126, 3.2±0.8 min, n=6 cells, 6 rats; P<0.05) (Fig. 3F-H). 
GF109203X reduced SP-induced firing time of lamina I neurons by 56.8±8.2% (control, 
10.01±1.8 min, n=10 cell, 8 rats; GF109203X, 4.33±0.82 min, n=7 cells, 4 rats; P<0.05). U0126 
and GF109203X reduced the number of SP-stimulated action potentials by 84±5% and 61±15% 
respectively, compared to controls. 
In addition to their role in endocytosis of GPCRs, dynamin and clathrin regulate vesicular 
transport and exocytosis, and thereby can control multiple components of synaptic transmission 
(27, 28). However, Dy4 did not affect the generation of excitatory post-synaptic currents 
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(EPSCs) in lamina I/IIo neurons in response to primary afferent stimulation (Fig. 3I,J). PS2 and 
Dy4 did not affect capsaicin-stimulated release of SP or calcitonin gene-related peptide (CGRP) 
from segments of mouse dorsal spinal cord (Fig. 3K,L).  
 Thus, NK1R endocytosis and resultant ERK and PKC signaling mediate sustained SP-
induced firing of spinal neurons. The effects of dynamin and clathrin inhibitors in the spinal cord 
are unrelated to changes in glutaminergic-mediated fast synaptic transmission or the exocytosis 
of neuropeptides. 
 
Clathrin, Dynamin, and βarrs Mediate NK1R Endocytosis and Nociception in Vivo 
 To determine the involvement of dynamin and clathrin in NK1R endocytosis in vivo, we 
injected Dy4, PS2, inactive analogues or vehicle intrathecally (L3/L4) to rats. After 30 min, 
vehicle or capsaicin was administered by intraplantar injection. The spinal cord was removed 10 
min later, and the NK1R was localized by immunofluorescence and confocal microscopy. In 
vehicle-treated control rats, the NK1R-IR was mostly at the plasma membrane of lamina I 
neurons (% NK1R-IR within 0.5 µm of plasma membrane: 80.7±1.6; n=3 rats, 6 neurons 
analyzed per rat; Fig. 4A,C, Movie S1). Intraplantar injection of capsaicin stimulated NK1R 
endocytosis (42.1±5.6; P=0.0027 to control (t-test); Movie S2). Intrathecal injection of Dy4 or 
PS2, but not inactive analogues, inhibited capsaicin-stimulated NK1R endocytosis (Dy4 59.6±0.2 
vs. Dy4 inact 49.9±0.8, P=0.0004; PS2 69.0±1.1 vs. PS2 inact 51.9±1.3, P=0.0135; Movies S3, 
S4; Fig. 4A,C). Painful peripheral stimuli activate ERK in NK1R-expressing spinal neurons, 
which contributes to hyperalgesia (25). Intraplantar capsaicin stimulated ERK phosphorylation in 
lamina I/II dorsal horn neurons (Fig. 4B,D). Dy4 or PS2 prevented capsaicin-stimulated ERK 
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activation in spinal neurons. Thus, painful stimuli induce clathrin- and dynamin-dependent 
NK1R endocytosis in spinal neurons, which is required for ERK signaling.  
Does NK1R endocytosis in spinal neurons mediate pain transmission? To evaluate the 
importance of the NK1R, clathrin and dynamin for nociception, we injected vehicle, NK1R 
antagonist SR140,333 (29), Dy4, PS2 or inactive analogues intrathecally (L3/L4) to mice. After 
30 min, vehicle or capsaicin was administered by intraplantar injection into one hindpaw. 
Withdrawal responses were measured to stimulation of the plantar surface of the ipsilateral 
(injected) and contralateral (non-injected) hindpaws with von Frey filaments, and edema was 
assessed by measuring thickness of the ipsilateral paw. In vehicle (intrathecal)-treated mice, 
capsaicin caused mechanical allodynia and edema for 4 h. SR140,333 caused a partial and 
transient inhibition of capsaicin-induced allodynia, whereas Dy4 and PS2, but not inactive 
analogues, caused a large and sustained inhibition of allodynia (Fig. 4E, fig. S4A). Edema was 
unaffected, confirming local action in the spinal cord (fig. S4B). 
Given the role of clathrin and dynamin in vesicular transport and synaptic transmission 
(27, 28), the antinociceptive actions of Dy4 and PS2 could be due to impaired motor responses 
rather than nociceptive transmission. However, Dy4 and PS2 did not affect withdrawal responses 
of the contralateral paw or rotarod latency, suggesting normal motor behavior (Fig. 4F,G). 
Intrathecal Dy4 also inhibited capsaicin-evoked mechanical allodynia in rat, which supports a 
role for dynamin in nociception in different species (fig. S4C). 
We used genetic approaches to disrupt endocytosis in view of possible off-target actions 
of dynamin inhibitors (30). Intrathecal injection of dynamin-1 siRNA knocked down dynamin-1-
IR (fig. S4D) and inhibited capsaicin-evoked allodynia after 24 h and 48 h in mice (Fig. 4H, fig. 
S4E). Intrathecal βarr1+2 siRNA knocked down βarr1+2 mRNA (fig. S4F) and inhibited 
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capsaicin-evoked allodynia at 36 h (Fig. 4I). siRNAs did not affect withdrawal responses of the 
contralateral paw (fig. S4G,H), consistent with normal motor function. 
Endocytosis and subsequent recycling mediate resensitization and sustained signaling of 
several GPCRs, including the NK1R (31). Thus, the antinociceptive actions of endocytic 
inhibitors could be due to disrupted resensitization of plasma membrane signaling rather than 
impaired endosomal signaling. Endothelin-converting enzyme-1, which is coexpressed with the 
NK1R in spinal neurons (22), degrades SP in endosomes and thereby promotes recycling and 
resensitization of the NK1R (32). However, intrathecal injection of SM-19712, an inhibitor of 
endothelin-converting enzyme-1 that prevents NK1R recycling and resensitization (32), had no 
effect on capsaicin-induced allodynia (Fig. 4J). These results suggest that the analgesic actions of 
endocytic inhibitors are unrelated to disrupted resensitization. Consistent with a role for NK1R 
endocytosis and βarrs in SP-evoked nuclear ERK signaling (9), intrathecal MEK inhibitor U0126 
inhibited capsaicin-evoked allodynia (25) (Fig. 4K). 
The effects of inhibitors of dynamin and clathrin on non-inflammatory and inflammatory 
pain were examined. Intrathecal injection of Dy4 and PS2 blunted both the early (non-
inflammatory) and late (inflammatory) phases of the nocifensive response to intraplantar 
formalin (Fig. 4L). When injected intrathecally 36 h after intraplantar injection of complete 
Freund’s adjuvant (CFA), which causes sustained inflammatory pain, inhibitors of dynamin and 
clathrin reversed pre-existing mechanical hyperalgesia (Fig. 4M). The NK1R was robustly 
internalized in spinal neurons of mice after intraplantar injection of capsaicin, formalin and CFA 
(fig. S5A-D). Intrathecal injection of Dy4 prevented capsaicin- and formalin-induced NK1R 
endocytosis, and reversed CFA-induced NK1R endocytosis. 
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These results suggest that clathrin and dynamin mediate pain-evoked endocytosis of 
NK1R in spinal neurons, which is required for nociception. 
 
Disruption of NK1R/βarr Interactions Inhibits NK1R Endocytosis and Nociception in Vivo. To 
substantiate involvement of NK1R endocytosis in nociception, we devised a pharmacological 
approach to inhibit NK1R/βarr interactions and NK1R endocytosis. G protein receptor kinases 
(GRKs) phosphorylate S/T-rich regions in the C-terminus of GPCRs, which interact with βarrs 
(33). A deletion mutant NK1Rδ311 lacks the C-terminus and corresponds to a naturally occurring 
NK1R variant (5) (Fig. 5A). NK1Rδ311 was normally expressed at the plasma membrane of 
HEK293 cells, but did not associate with βarrs or internalize (Fig. 5B,C, fig. S6A-C). In HEK-
NK1Rδ311 cells, SP stimulated cytosolic but not nuclear ERK, and did not affect transcription 
activity, consistent with endocytosis-dependent nuclear ERK signaling and transcription (Fig. 
5D,E). Peptides corresponding to predicted phosphorylation sites in the C-terminus of mouse 
NK1R were conjugated to membrane-penetrating Tat peptide (Fig. 5A). A combination of three 
peptides inhibited SP-induced NK1R-RLuc8/βarr2-YFP BRET and prevented SP-induced NK1R 
endocytosis, compared to a control peptide, suggesting effective disruption of NK1R/βarr 
interactions (Fig. 5F,G). When injected intrathecally, inhibitors of NK1R/βarr interactions 
suppressed capsaicin-evoked allodynia and formalin-induced nociceptive behavior, and reversed 
CFA-induced hyperalgesia (Fig. 5H-J). Together, these results support a role for βarr-mediated 
NK1R endocytosis and endosomal signaling in nociception. 
 
Lipid Conjugation Delivers NK1R Antagonists to Endosomes and Selectively Blocks Sustained 
Endosomal Signals 
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 We observed that clathrin, dynamin and βarr inhibitors and siRNA, including selective 
inhibitors of NK1R/βarr interactions, suppress SP-induced NK1R endocytosis, 
compartmentalized signaling, transcription and neuronal excitability, and have anti-nociceptive 
actions. These findings support the hypothesis that endosomal NK1R signaling underlies 
sustained neuronal excitation and nociception. Thus, selective antagonism of endosomal 
receptors could be an effective treatment for pain. To investigate this possibility, and to provide 
direct evidence for the importance of endosomal signaling for nociception, we devised a novel 
approach to deliver and concentrate GPCR antagonists in early endosomes. 
Lipid conjugation anchors drugs at membrane surfaces and promotes endosomal delivery 
(34). We synthesized tripartite probes comprising cholestanol (Chol, promotes membrane 
insertion, anchoring) or ethyl ester (control, no membrane anchoring), a flexible polyethylene 
glycol (PEG) linker, and a cargo of either cyanine 5 (Cy5) for localization, or spantide I (Span), a 
peptidic membrane impermeant NK1R antagonist (35) (Fig. 6A). Some probes were labeled with 
Span and cyanine 5. When incubated with HEK293 cells, Cy5-Chol inserted into the plasma 
membrane within 5 min, whereas Cy5-Ethyl ester remained entirely extracellular (Fig. 6B, 
Movies S5, S6). After 4 h of continuous incubation, Cy5-Chol was concentrated in Rab5a-
positive early endosomes, although Cy5-Chol was also detected at the plasma membrane (Fig. 
6C). When incubated with HEK-NK1R-GFP cells for 4 h, Cy5-Chol also colocalized with NK1R-
GFP in endosomes (cells were stimulated with SP to induced NK1R endocytosis) (Fig. 6C). 
When HEK-NK1R-GFP cells were pulse-incubated with Cy5-Chol for 30 or 60 min, washed, and 
allowed to recover for 4 h, Cy5-Chol was gradually removed from the plasma membrane and 
accumulated in NK1R-GFP-positive endosomes, although some probe remained at the plasma 
membrane (fig. S7A, C). Cy5-Ethy ester was not taken up by cells after pulse-incubation (fig. 
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S7B). Quantification of Cy5-Chol uptake after 30 min pulse-incubation, indicated that 69% of 
cell-bound probe was internalized at 4 h and 79% at 8 h after washing (fig. S7D). After pulse 
incubation, Cy5-Span-Chol trafficked to NK1R-GFP-positive endosomes (Fig. 6C). Dy4 
inhibited uptake of Chol-conjugated tripartite probes, consistent with constitutive dynamin-
mediated endocytosis (fig. S7E). 
 We used FRET to quantify association of tripartite probes with the NK1R in endosomes. 
NK1R with extracellular N-terminal SNAP-Tag® was expressed in HEK293 cells and cell-surface 
NK1R was labeled with membrane impermeant SNAP-Surface™-549. SP (10 nM, 30 min) evoked 
translocation of SNAP-549-NK1R to endosomes (Fig. 6D). Cells were treated with Cy5-Chol, and 
FRET between SNAP-549-NK1R and Cy5-Chol was measured in regions of interest within the 
cytosol. Cy5-Chol/SNAP-549-NK1R FRET was detected after 5 min and increased for 60 min (Fig. 
6D, E, Movie S7). FRET was not detected in control cells lacking NK1R (Fig. 6E). 
Span-Chol antagonized SP (3 nM, EC80)-stimulated Ca2+ signaling in HEK-NK1R cells 
(pIC50 Span, 8.23±0.21; Span-Chol 8.44±0.29) and thus retains activity. Since the tripartite probe 
was concentrated in endosomes after 4 h, we examined NK1R endosomal signaling 4 h after 
preincubation with antagonists. When HEK-NK1R cells were preincubated with Span-Chol, Span 
or SR140333 for 30 min, and then immediately challenged with SP, all antagonists blocked 
nuclear ERK (Fig. 6F, H) and cytosolic ERK (fig. S8A, C) activity, indicating effective 
antagonism of cell-surface NK1R. When cells were pulse-incubated with antagonists for 30 min, 
washed, and stimulated with SP 4 h later (to allow lipidated antagonists to concentrate in 
endosomes), Span-Chol alone inhibited nuclear ERK (derives from endosomal NK1R) (Fig. 6G, 
H) and no antagonist inhibited cytosolic ERK (derives from plasma membrane NK1R) (fig. S8B, 
C). Span-Chol also prevented SP-induced transcription. HEK-NK1R cells were incubated with 
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Span or Span-Chol for 30 min, washed, recovered for 4 h, and then stimulated with SP for 20 h. 
Span-Chol abolished SP-stimulated SRE-SEAP secretion (derives from endosomal NK1R), 
whereas unconjugated Span was ineffective (Fig. 6I). However, when continuously incubated 
with antagonists, both Span-Chol and Span inhibited transcription. Span-Chol did not affect 
isoprenaline-induced activation of nuclear ERK, which is mediated by the endogenous β2-
adrenergic receptor (fig. S8D). Thus, the effects of tripartite antagonists are not mediated by a 
non-specific disruption of endosomal signaling. 
The results show that lipid conjugation promotes the effective delivery and retention of 
antagonists to endosomes containing the NK1R. After pulse incubation, Span-Chol causes 
sustained and selective antagonism of endosomal not plasma membrane NK1R. Unconjugated 
Span and SR140,333, a potent small molecule antagonist, are unable to effectively inhibit 
persistent NK1R signaling in endosomes. 
 
Endosomally Targeted NK1R Antagonists Block Nociception 
To assess whether antagonism of the endosomal NK1R blocks sustained SP-induced 
excitation of spinal neurons, we incubated slices of rat spinal cord with Span-Chol or Span for 60 
min, washed, and challenged with SP 60 min later. In vehicle- or Span-treated slices, SP caused 
brisk firing that was sustained after washout (Fig. 7A-C). As observed with endocytic inhibitors, 
Span-Chol did not suppress the initial excitation, but prevented sustained excitation. The SP-
induced firing rate (2 min normalized) was (events.2 min-1) Span-Chol, 196.6±81.6, and Span, 
242.6±95.9 (P<0.05). 
 To evaluate whether endosomal targeting improves the efficacy and duration of action of 
NK1R antagonists for the treatment of pain, we administered cholestanol-conjugated or 
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conventional antagonists by intrathecal injection 3 h before intraplantar injection of capsaicin. 
This time was selected to allow endosomal accumulation of lipidated antagonists. When Cy5-
Chol was injected intrathecally, probe was detected in laminae I-III neurons after 3-6 h, 
confirming delivery and retention in pain-transmitting neurons (Fig. 7D). Cy5-Chol did not 
affect nociception, which excludes non-specific actions of cholestanol (Fig. 7E). Span-Chol, but 
not Span or SR140333, inhibited capsaicin-evoked mechanical allodynia (Fig. 7E). When 
administered 30 min after capsaicin, intrathecal Span was transiently antinociceptive, whereas 
Span-Chol caused a delayed (3 h), persistent (6 h) and substantial (>50%) antinociception (Fig. 
7F). 
 The small molecule NK1R antagonist L-733,060 (36) conjugated to Chol antagonized SP 
(3 nM, EC80)-stimulated Ca2+ signaling in HEK-NK1R cells (% inhibition, 1 nM SP: 10 nM L-
733,060, 40.8±8.9; 10 nM L-733,060-Chol, 71.1±9.2) and thus retained activity. When injected 
intrathecally 3 h before intraplantar capsaicin, L-733,060-Chol was antinociceptive from 1-4 h, 
whereas L-733,060 was antinociceptive only at 1 h (Fig. 7G). 
 When injected intrathecally 3 h before intraplantar formalin, Span-Chol inhibited both 
phases of nocifensive behavior more completely than Span or SR140333 (Fig. 7H). When 
injected intrathecally 36 h after intraplantar CFA, Span-Chol inhibited mechanical hyperalgesia 
from 1-6 h, whereas the antinociceptive actions of Span and SR140333 were minor and transient 
for Span (Fig. 7I, J).  
The enhanced potency and duration of action of lipidated antagonists could be due to 
improved metabolic stability rather than appropriate targeting of endosomal NK1R. However, 
Span and Span-Chol were similarly stable in human cerebrospinal fluid (Fig. 7K). Thus, 
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enhanced stability does not account for the sustained antinociceptive actions of cholestanol-
conjugated antagonists. 
 Collectively, our results reveal, for the first time, the importance of endosomes as 
platforms for GPCR compartmentalized signaling that underlies sustained excitation of spinal 
neurons and nociception, and show that targeting endosomal GPCR signaling provides a novel 
alternative for sustained pain relief. 
 
Discussion  
 Our results support a reinterpretation of the notion that the primary physiological actions 
of GPCRs in vivo are mediated by cell-surface receptors. By studying the NK1R as a prototypical 
GPCR that traffics to endosomes, we show that endosomal receptors convey sustained signals 
that underlie excitation and nociceptive transmission in spinal neurons, and that targeting these 
receptors in endosomes is required for optimal pharmacological intervention. 
We report that endosomal GPCRs generate a spectrum of signals in subcellular 
compartments. Clathrin and dynamin disruption prevented NK1R endocytosis, and inhibited 
activation of nuclear ERK, cytosolic PKC and cytosolic cAMP. Dynamin inhibitors also blocked 
SP-induced transcription, which is likely mediated by nuclear ERK. A C-terminally truncated 
mutant, NK1Rδ311, was also unable to internalize, activate nuclear ERK, or stimulate 
transcription. Gαq inhibition blocked NK1R endosomal signals, and endosomes contained both 
activated NK1R and Gαq. Our results are consistent with the hypothesis that the NK1R in 
endosomes signals by Gαq-dependent processes that activate nuclear ERK, cytosolic PKC and 
cytosolic cAMP to cause nociception (Fig. 8A, Movie S8). By delivering activated NK1R to 
endosomes and serving as a scaffold for signaling complexes, βarrs facilitate these signals (9, 22, 
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23). Our findings add to the growing number of GPCRs, including β2-adrenergic and thyroid 
stimulating hormone receptors (11, 12), known to signal from endosomes by G protein-
dependent processes, and provides the first in vivo evidence, to our knowledge, that this 
endosomal mechanism is physiologically relevant. 
Pharmacological and genetic disruption of clathrin, dynamin and βarrs blocked SP-
induced excitation of spinal neurons, attenuated pain-evoked NK1R endocytosis and ERK 
activation in spinal neurons, and suppressed nociception. Inhibitors of MEK and PKC suppressed 
sustained SP-induced excitation of spinal neurons, which likely requires compartmentalized 
ERK and PKC signaling. A MEK inhibitor also blocked nociception. These findings suggest that 
endosomal NK1R signaling is necessary for sustained excitation of spinal neurons and 
nociceptive transmission in the spinal cord, and reveal, for the first time, a vital link between 
endosomal signaling and nociception. 
 Our results provide new information about the contribution of clathrin and dynamin to 
SP-induced excitation of spinal neurons and nociceptive transmission (Fig. 8B). Although the 
effects of endocytic inhibitors on NK1R internalization and nociception are consistent with a role 
for NK1R endocytosis in pain, clathrin and dynamin mediate endocytosis and exocytosis of many 
GPCRs, ion channels and neuropeptides that control pain transmission  (27, 28). However, the 
findings that selective disruption of NK1R-βarr interactions using membrane-permeant peptides, 
and specific antagonism of endosomal NK1R with lipidated antagonists, effectively suppress 
neuronal excitation and nociception in several models, provide direct support for a major 
contribution of the endosomal NK1R to pain. Clathrin and dynamin inhibitors did not affect fast 
synaptic transmission in the spinal cord or capsaicin-evoked neuropeptide release from spinal 
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terminals of nociceptors, and had no effect on motor coordination in vivo. These results suggest 
that synaptic transmission and vesicular transport were unaffected. 
 Our discovery that endosomes are platforms for compartmentalized GPCR signaling that 
underlies pathophysiologically important processes in vivo has therapeutic implications. Delivery 
of antagonists to endosomes may facilitate the disruption of sustained signals from endosomal 
GPCRs that underlie disease, and could provide enhanced efficacy and selectivity (Fig. 8C). The 
accumulation of tripartite probes in NK1R-positive endosomes demonstrates the feasibility of 
endosomal delivery. The capacity of Span-Chol, L-733,060-Chol, but not unconjugated 
antagonists, to specifically antagonize endosomal NK1R signaling and sustained excitation of 
spinal neurons, and to cause prolonged and more effective antinociception demonstrates the 
importance of endosomal signaling for pain, and illustrates the therapeutic utility of 
endosomally-directed drugs. Lipidated antagonists were able to both prevent and reverse 
nociception, demonstrating therapeutic efficacy. The NK1R redistributes from the plasma 
membrane to endosomes in chronic inflammatory and neurological diseases that are associated 
with persistent SP release (5). Conventional antagonists are designed to target GPCRs at the cell-
surface. We propose that the inability of conventional antagonists to effectively target the NK1R 
in endosomes, where the receptor assembles a multi-protein signalosome in an acidic 
environment, contributes to their lack of clinical success (5). 
Herein we report that endosomal GPCR signaling is a critical mediator and a viable 
therapeutic target for pain. Given that many activated GPCRs internalize, and that GPCRs 
participate in most pathophysiological processes and are the target of one third of approved 
drugs, our study suggests that therapeutic targeting of endosomal GPCRs is a new paradigm of 
drug delivery that offers more effective and selective treatments for disease. 
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Materials and Methods 
Supplementary Materials and Methods provide complete methods. 
Animals. Institutional Animal Care and Use Committees approved all studies. Animals were 
maintained in a temperature-controlled environment with a 12 h light/dark cycle and free access 
to food and water.  
Tripartite probes. Sulfonated cyanine 5 carboxylic acid, Span I and L-733,060 were conjugated 
to cholestanol or aspartate ethyl ester via a flexible PEG linker by standard Fmoc solid-phase 
peptide synthesis, and were analyzed by LCMS (fig. S9, fig. S10). 
Alexa568-SP. SP was labeled with AlexaFluor568 NHS ester and purified by reverse-phase 
HPLC.  
NK1R-βarr inhibitors. Peptides were synthesized corresponding to predicted phosphorylation 
sites in the C-terminus of the mouse NK1R (S398SSFYSNM405, S390NSKTMTE397, 
L382TSNGSSR389) or control peptide (MSNSYSFS) with N-terminal Tat sequence 
(YGRKKRRQRRR). 
cDNAs. cDNAs have been described encoding sensors for BRET (37, 38) and FRET (39-42). 
cDNAs have been reported encoding full length and truncated δ311 rat HA-NK1R (43), GFP-
dynamin and GFP-dynamin K44E (19). 
Cell lines, transfection. HEK293 cells stably expressing rat HA-NK1R have been described 
(32). HEK293 cells were transiently transfected as described (23). 
BRET. HEK293 cells were transfected with the BRET sensors, and BRET ratios were 
determined after 48 h, as described (23). 
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FRET biosensors of compartmentalized signaling. HEK293 cells were transfected with NK1R, 
FRET biosensors, and siRNA, and FRET was assessed after 48 or 72 h, as described (20, 23). 
FRET assays of endosomal NK1R targeting. HEK293 cells were transfected with SNAP-Tagged® 
NK1R. After 48 h, the cell-surface NK1R was labeled with SNAP-Surface™ 549 photostable 
fluorescent substrate. Cells were washed, recovered for 30 min, and stimulated with SP to induce 
NK1R endocytosis. Cells were incubated with Cy5-Chol. SNAP-549/Cy5 sensitized emission FRET 
was measured by confocal imaging. 
Transcription assays. HEK293 cells were transfected with NK1R or NK1Rδ311 and SEAP 
reporter gene under the control of the SRE consensus sequence. Some cells were also transfected 
with dynamin WT, dynamin K44E or pcDNA3. After 48 h, cells were then stimulated with 
vehicle or SP for 4 or 20 h. SEAP activity was determined as described (44). 
Ca2+ assays. [Ca2+]i was measured as described (23). 
Cell-surface ELISA. HEK293 cells transiently transfected with HA-NK1R or HA-NK1Rδ311 
were fixed. Detergent permeabilized or non-permeabilized cells were incubated with anti-HA, 
followed by anti-mouse horseradish peroxidase-conjugated antibody, which was detected using a 
colorimetric assay. 
NK1R trafficking in cell lines. HEK-NK1R cells were incubated with Alexa568-SP (100 nM, 20 
min, 4°C), washed, incubated for 30 min at 37°C, and fixed. To examine NK1R and Gαq 
trafficking, cells were incubated in HBSS with SP (100 nM, 15 min) or vehicle and fixed. NK1R, 
Gαq and EEA1 were detected by immunofluorescence (23). 
Inhibitors. HEK293 cells were preincubated for 30 min with 30 µM Dy4, Dy4 inactive (17), 
PS2, or PS2 inactive (18), 100 nM UBO-QIC, 1 µM U73122, 10 µM NF449, 1 µM GF109203X, 
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100 µM EGTA, 30 µM each of cell penetrating NK1R peptides, 100 µM control peptide or 
vehicle. 
Cy5 tripartite probe uptake. HEK293 cells were infected with CellLight® Rab5a-RFP or were 
transfected with rat NK1R-GFP. Uptake of Cy5-Chol, Cy5-Ethyl ester or Cy5-Span-Chol was 
examined in live cells by confocal imaging. 
Spinal cord slices. Parasagittal slices were prepared from rat lumbar spinal cord as described 
(45). 
Electrophysiology. Spontaneous currents were recorded in NK1R-positive lamina I neurons in 
cell-attached configuration using patch electrodes (45). Slices were preincubated with Dy4 or 
Dy4 inact (30 µM, 10 min) or with U0126 or GFX109203X (1 µM, 30-45 min) before recording. 
Slices were preincubated with Span-Chol or Span (1 µM, 60 min), washed and incubated in 
antagonist-free medium for a further 60 min. Slices were challenged with SP (1 µM, 2 min). The 
firing rate for each cell was normalized to the response at the 2 min time point and firing time 
was determined as the duration of the response to last action potential. To assess NK1R 
endocytosis, spinal cord slices were incubated with SP (1 µM, 5 min), fixed and processed to 
localize NK1R.  
Neuropeptide release. Neuropeptide release was measured from superfused segments of mouse 
dorsal spinal cord as described (46). Tissues were superfused with Dy4, PS2, inactive analogues 
(30 µM) or vehicle (0.3% DMSO/saline) for 30 min. Tissues were then superfused with 
capsaicin (0.3 µM, 10 min) in the presence of inhibitors or controls. Superfusate was analyzed 
for SP and CGRP by ELISA. 
NK1R endocytosis in rat spinal neurons. Dy4, Dy4 inact, PS2, PS2 inact (50 µM), or vehicle 
(1% DMSO/saline) was injected intrathecally (10 µl, L3/L4) into conscious rats. After 30 min, 
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capsaicin (12.5 µg) or vehicle (20% ethanol, 10% Tween 80, 70% saline) was injected 
subcutaneously into the plantar surface of one hindpaw (25 µl). After 10 min, rats were 
transcardially perfused with fixative. NeuN, NK1R and phospho-ERK were localized by 
immunofluorescence (47, 48).  
Nociception in mice and rats, NK1R endocytosis in spinal neurons in mice. Withdrawal 
responses to stimulation of the plantar surface of the hind-paw with graded von Frey filaments 
and paw edema were measured as described (47, 48). Capsaicin (5 µg), Complete Freund’s 
Adjuvant (CFA, 2 mg.ml-1), or vehicle (capsaicin, 20% ethanol, 10% Tween 80, 70% saline; 
CFA, saline) was injected into the plantar surface of the left hindpaw (10 µl). von Frey scores 
(left and right paws) and paw thickness (left paw) were measured for 30-240 min after capsaicin, 
and 36-40 h after injection of CFA. Results are expressed as percent pre-injected values. 
Formalin (4%, 10 µl) was injected into the plantar surface of the left hindpaw. Nocifensive 
behavior (flinching, licking, biting of the injected paw) was recorded for 60 min. At the end of 
experiments, mice were transcardially perfused with PBS and PFA, and the spinal cord was 
removed and processed to localize the NK1R by immunofluorescence. Investigators were 
unaware of test agents. 
Intrathecal injections in mice. Dy4, Dy4 inact, PS2, PS2 inact (all 50 µM), SR-140333 (15 
µM), SM-19712 (8 mM), U0126 (100 µM), 30 µM each of cell penetrating NK1R peptides, 100 
µM control peptide, or vehicle (1% DMSO/saline) was injected intrathecally (5 µl, L3/L4) 30 
min before intraplantar injection of capsaicin or formalin, or 36 h after CFA. Span (50 µM), 
Span-Chol (50 µM), L-733,060 (100 nM), L-733,060-Chol (100 nM), or Cy5-Chol (10 µM) was 
injected intrathecally 3 h before or 30 min after intraplantar injection of capsaicin, 3 h before 
formalin, or 36 h after CFA.  
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Intrathecal siRNA in mice. Cationic liposome and adjuvant anionic polymer  (49) were used to 
deliver siRNA targeting mouse dynamin-1  (50), mouse βarr1 plus mouse βarr2 or control 
siRNA. siRNA lipoplexes were administered by intrathecal injection (L1-L4, 5 µl). After 
behavioral testing (24-48 h), the spinal cord (L1-L4) was collected for analysis of dynamin-1 and 
βarr1 and βarr2 expression.  
Assessment of siRNA knockdown. Knock-down of siRNA targets in cell lines and spinal cord 
was confirmed by Western blot and q-PCR.  
Rotarod latency. Baseline time trials (cut-off 120 s) were recorded. Dy4, PS2, inactive 
analogues (50 µM), or vehicle was injected intrathecally (5 µl, L3/L4). After 30 min, mice were 
placed on the rotarod with accelerating velocity for up to 120 s. Latency time to fall was 
determined at 30, 90 and 120 min. 
Confocal microscopy, image analysis. Samples were observed using a Leica SP8 confocal 
microscope. Z stacks were collected of NK1R-positive neurons in lamina I of the dorsal horn. 
NK1R endocytosis and pERK expression were quantified using ImageJ. The ratio of plasma 
membrane to cytosolic NK1R-IR fluorescence was determined to assess endocytosis. To quantify 
ERK activation, the ratio of the number of pERK-IR neurons to total NeuN-N-positive neurons 
in lamina I/II was determined.  
Super-resolution microscopy. Cells were observed using a Leica DMI6000 Ground State 
Depletion microscope. The number of EEA1-IR endosomes per cell containing NK1-IR and Gα-
IR in endosomes was determined. 
Metabolic stability of tripartite probes. Span or Span-Chol (10 µg.ml-1) was incubated in 
human cerebrospinal fluid (0-4 h, 37°C). Samples were analyzed by LC/MS. Peptides were 
quantified by comparison to calibration standards (50-50,000 ng.ml-1). 
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Statistical analyses. Data are presented as mean±SEM, unless noted otherwise. Differences 
were assessed using Student's t test for two comparisons. For multiple comparisons, differences 
were assessed using one- or two-way ANOVA followed by Dunnett’s multiple comparison test, 
Tukey’s multiple comparison test, Sidak’s multiple comparisons test, or Dunn’s multiple 
comparisons test (table S1). 
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Fig. 1. NK1R endocytosis-dependent compartmentalized signaling. A-I. Effect of inhibitors 
of dynamin (Dy4) and clathrin (PS2), and of inactive (inact) analogues, on SP-induced 
spatiotemporal signaling profiles for nuclear ERK (NucEKAR, A-C), cytosolic PKC 
(CytoCKAR, D-F), cytosolic cAMP (CytoEpac2, G-I) measured in HEK293 cells using FRET 
biosensors. B, E, H. Representative ratiometric images and sensor localization. Max: response to 
positive controls. C, F, I. Area under curve (AUC) of A, D, G. J, K. Effect of dynamin WT (J) 
or dominant negative K44E (K) overexpression on the spatiotemporal profile of SP-induced 
nuclear ERK. L. AUC of J, K. M. Effect of clathrin heavy chain and dynamin-1 siRNA on the 
spatiotemporal profile of SP-induced nuclear ERK. N. AUC of M. O. Effect of dynamin WT or 
K44E overexpression on the SP-induced SRE-SEAP. **P<0.01, ***P<0.001 to vehicle (Veh); 
^^P<0.01, ^^^P<0.001 control to inhibitors. A-N, 30-354 cells, 3-5 experiments, O, n=3-5 
experiments. ANOVA, Tukey’s test (C, F, I, N); Sidak’s test (L); Dunnett’s test (O). 
Fig. 2. G protein-dependent NK1R signaling in endosomes. A-D. SP-induced BRET between 
NK1R-RLuc8 and KRas-Venus or Rab5a-Venus, and between Gαq-RLuc8/Gγ2-Venus or Rab5a-
Venus in HEK293 cells. *P<0.05, **P<0.01, ***P<0.001 to baseline. Triplicate observations, 
n>3 experiments. E, F. NK1R-IR (green), Gαq-IR (cyan), EEA1-IR (red) localization by super-
resolution microscopy. Blue boxes, plasma membrane; red boxes, endosomes. 60-66 cells per 
condition (20-22 cells from n=3 experiments). ****P<0.0001. G-I. Effect of inhibitors of Gαq 
(UBO-QIC) or PLC (U73122), Ca2+-chelation (EGTA), or inhibitors of  Gαs (NF449) or PKC 
(GF109203X, GFX) on SP-induced nuclear ERK, cytosolic PKC and cytosolic cAMP measured 
using FRET biosensors (AUC, area under the curve). ***P<0.001 SP to vehicle; ^^^P<0.001 
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control to inhibitor. 35-67 cells, 3 experiments. ANOVA, Dunnett’s test (A-D); Sidak’s test (F, 
G); Tukey’s test (H, I). 
Fig. 3. NK1R endocytosis and neuronal excitation in spinal cord slices. A. Effect of Dy4 and 
Dy4 inact on SP-induced endocytosis of NK1R-IR in rat spinal neurons. Arrows, internalized, 
arrowheads, cell surface NK1R. B. Quantification of endocytosis. ****P<0.0001. 18 neurons per 
group (6 neurons in slices from n=3 rats). C-H. Effects of Dy4, Dy4 inact, U0126 (MEK 
inhibitor) and GF109203X (PKC inhibitor) on SP-induced firing of rat spinal neurons. C, F. 
Representative traces. D, G. Firing rate normalized to 2 min. E, H. Firing duration to last action 
potential. 6-7 neurons per group from n=8-17 rats. *P<0.05, **P<0.01, ***P<0.001. I, J. Effect 
of Dy4 and Dy4 inact on excitatory post-synaptic currents (EPSC) in lamina I/IIo induced by 
primary afferent stimulation. n=11 neurons. K, L. Effects of Dy4, PS2 and inactive analogues on 
capsaicin-stimulated SP-IR (K) and CGRP-IR (L) release from segments of mouse spinal cord. 
n=6 experiments. ANOVA, Tukey’s test (B); Sidak’s test (D, G); Dunn’s test (E, H). 
Fig. 4. NK1R endocytosis, ERK signaling and nociception in vivo. Effects of intrathecal (i.t.) 
injections of inhibitors or siRNA. A-B. Localization of NK1R-IR (A) and pERK-IR (B) in rat 
spinal neurons 10 min after intraplantar (i.pl.) vehicle or capsaicin (Cap). L, lamina. In A, 
arrowheads show cell-surface and arrows show endosomal NK1R. In B, arrows show pERK-IR 
(green) and red shows NeuN (neuronal marker). C, D. Quantification of NK1R endocytosis (C) 
and pERK-expressing neurons (D). **P<0.01, ***P<0.001. Neuronal numbers: Veh, 54; 
capsaicin, 52; Dy4, 28; Dy4 inact, 18; PS2, 22; PS2 inact, 19 (>6 neurons in sections from n=3 
rats). E, F, H-K. Nociception in mice after intrathecal injection of endocytic inhibitors (Dy4, 
PS2), NK1R antagonist (SR140,333; SR), dynamin-1 or βarr1+2 siRNA, endothelin-converting 
enzyme-1 inhibitor (SM-19712; SM), or MEK inhibitor (U0126). von Frey withdrawal responses 
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of capsaicin-injected (E, H-K) or contralateral (F) paw are shown. G. Rotarod latency. L. 
Formalin (form) nocifensive behavior. M. von Frey withdrawal responses of the CFA-injected 
paw. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 to control. (n) mouse number. Student’s t-
test (C, D); ANOVA, Dunnett’s test (E-M). 
Fig. 5. Disruption of NK1R/βarr interactions. A. Mouse NK1R C-terminus, indicating 
NK1Rδ311 truncation and sequences of Tat-conjugated NK1R and control peptides. B, C. SP-
induced BRET between WT NK1R-RLuc8 or NK1Rδ311-RLuc8 and βarr2-YFP or Rab5a-
Venus. Triplicate observations, n>3 experiments. D. SP-induced cytosolic ERK (CytoEKAR), 
nuclear ERK (NucEKAR) measured using FRET biosensors. *P<0.05. 49-99 cells, 3 
experiments. E. Effect of SP on SRE-SEAP release from HEK-NK1Rδ311 cells. F, G. Effect of 
control and 3 NK1R peptides on SP-induced NK1R-Rluc8/βarr2-YFP BRET (F) and NK1R 
endocytosis (G). H-I. Effects of intrathecally administered control and NK1R peptides on 
capsaicin-induced mechanical allodynia (H), formalin-evoked nocifensive behavior (I) and CFA-
induced mechanical hyperalgesia (J) in mice. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 
to control. (n) mouse number. ANOVA, Sidak’s test (D, G); Dunnett’s test (H-J). 
Fig. 6. Antagonism of endosomal NK1R. A. Structure of tripartite probes. B. Cy5-Ethyl ester or 
Cy5-Chol uptake in HEK293 cells. C. Cy5-Chol or Cy5-Span-Chol (red) trafficking to Rab5a-
RFP- (blue) and NK1R-GFP-positive (green) endosomes. Asterisk, extracellular; arrowheads, 
plasma membrane; arrows, endosomes. D, E. Cy5-Chol:SNAP549-NK1R FRET, indicating 
localization of  SNAP549-NK1R, Cy5-Chol and FRET signals (D), and time course of FRET in the 
whole cell and cytosol (E). *P<0.05, **P<0.001 to control; ^^^P<0.001 control to inhibitors. 6-9 
cells, n=3 experiments. F-H. FRET assays of nuclear ERK activity (NucEKAR) immediately after 
(pre-incubation, F) or 4 h after (pre-pulse, G) a 30 min incubation with Span, Span-Chol or 
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SR140333 (SR). H. AUC of G, H. **P<0.01, ***P<0.001 to vehicle; ^^^P<0.001 to antagonists. 
31-417 cells, n=3-5 experiments. I. Effects of Span or Span-Chol on SP-induced SRE-SEAP. 
ANOVA, Sidak’s test (H). 
Fig. 7. Antagonism of endosomal NK1R in spinal cord slices and in vivo. A-C. Effects of 
tripartite antagonists on SP-induced firing of rat spinal neurons. A. Representative traces. B. 
Firing rate normalized to 2 min. C. Firing duration to last action potential. 6-7 neurons per group 
from n=5-18 rats. D. Localization of Cy5-Chol (arrows) in superficial laminae (L) 6 h after 
intrathecal injection in mouse. E-J. Effects of intrathecally administered Cy5-Chol, Span, Span-
Chol, L-733,066 (L733) or L-733,0660-Chol on nociception in mice. E-G. Von Frey withdrawal 
responses of capsaicin-injected paw. H. Nocifensive behavior after intraplantar formalin. I, J. 
Von Frey withdrawal responses of CFA-injected paw. (n) mouse number. *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001 to control. I. Kinetics of degradation of Span and Span-Chol in human 
cerebrospinal fluid. n=2, mean ± SD. ANOVA, Sidak’s test (B); Dunn’s test (C); Dunnett’s test (E-J). 
Fig. 8. Endosomal platforms for signaling pain. A. Nociceptive signaling. NK1R couples to 
Gαq (1), PLC-dependent Ca2+ mobilization (2), and A Disintegrin And Metalloproteinase- 
(ADAM)-dependent epidermal growth factor receptor (EGFR) transactivation, which stimulates 
cytosolic ERK (4). Ca2+ activates PKC, which stimulates adenylyl cyclase (AC) to produce 
plasma membrane cAMP (5). GRK-phosphorylated NK1R interacts with βarrs (6), which 
scaffold clathrin and adaptor protein 2 (AP2), leading to SP/NK1R endocytosis (7). Endosomal 
SP/NK1R (8) stimulates cytosolic PKC activity, cytosolic cAMP, and nuclear ERK activity (9), 
which drive neuronal excitation and nociceptive transmission. B. Antinociception, endocytic 
inhibitors. Inhibition of dynamin (1), clathrin (2), or βarrs (3) prevents SP/NK1R endocytosis, 
endosomal signaling and nociceptive transmission. C. Antinociception, tripartite antagonists. 
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Tripartite antagonists incorporate into the plasma membrane (1), traffic to endosomes (2), and 
suppress SP/NK1R nociceptive signaling. 
